I will turn to my colleagues here, Arianne and Michael, in a moment, but I think those negotiations or discussions started in advance, but not too far in advance, and one of the things we wanted to do, just as with the vaccine portfolio itself, was to get some diversification, because these syringes were obviously in high demand across the globe, so you didn't want to be reliant on just one supplier. We now have supplies coming from a number of sources.
Arianne or Michael, do you want to touch on when we started negotiations? I must admit it feels like a distant memory.